Akcea Therapeutics Inc. filed an application with the European Medicines Agency, seeking approval for a treatment of a rare genetic disorder.

Volanesorsen is meant for patients with the familial chylomicronemia syndrome which results in abdominal pain and potentially fatal bouts of pancreatitis, the inflammation of the pancreas.

Akcea, a unit of Ionis Pharmaceuticals Inc., will also file applications for its drug in Canada and the U.S. in September.